Drugs are an acquired source of biological variance among patients

Journal of Psychiatric Practice

Volumn 12, Issue 6, 2006, Pages 391-396

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Montreal   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; FLUOXETINE; NEUROLEPTIC AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; PHARMACOGENOMICS; POLYPHARMACY; PRESCRIPTION; PSYCHOPHARMACOLOGY; REVIEW; RISK FACTOR; UNITED STATES;

DRUG INTERACTIONS; HEALTH STATUS; HUMANS; MENTAL DISORDERS; PATIENTS; POLYPHARMACY; PSYCHIATRY; PSYCHOTROPIC DRUGS;

EID: 33751521153     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200611000-00006     Document Type: Review

References (49)

1. Preskorn SH, Lacey RL. Polypharmacy: When is it rational? J Psychiatric Practice (formerly the Journal of Practical Psychiatry and Behavioral Health) 1995;1:92-8 (Can be accessed at http://www.preskorn.com/columns/9507.html).
2. Preskorn SH. The rationale for and clinical implications of dose-response curves. Series of columns published in Journal of Psychiatric Practice (formerly the J Practical Psychiatry and Behavioral Health).Can be accessed at www.preskorn.com/column3.html.
3. Preskorn SH. Modern drug development and the Human Genome Project. Series of columns published in Journal of Psychiatric Practice (formerly the J Practical Psychiatry and Behavioral Health). Can be accessed at www.preskorn.com/column4.html.
4. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics. Health, United States 2004. Hyattsville, MD, 2004 Can be accessed at www.cdc.gov/nchs/hus.htm.
5. Bjerrum L, Rosholm JU, Hallas J, et al. Methods for estimating the occurrence of polypharmacy by means of a prescription database. Eur J Clin Pharmacol 1997;53:7-11.
6. Bjerrum L, Segaard J, Hallas J, et al. Polypharmacy: correlations with sex, age and drug regimen. A prescription database study. Eur J Clin Pharmacol 1998;54:197-202.
7. Davies SJC, Eayrs S, Pratt P, et al. Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol 2004;57:464-72.
8. Davies SJC, Lennard MS, Ghahramani P, et al. PRN prescribing in psychiatric inpatients - Potential for pharmacokinetic drug interaction. Presented at 9th International Meeting of Clinical Pharmacology in Psychiatry. Oxford, England. Sep. 24-27: 2005.
9. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States. JAMA 2002;287:337-44.
10. Rosholm JU, Bjerrum L, Hallas J, et al. Polypharmacy and the risk of drug-drug interactions among Danish elderly: A prescription database study. Dan Med Bull 1998;45:210-13.
11. Preskorn SH. Drug approvals and withdrawals over the last 60 years. J Psychiatr Pract 2002;7:41-50.
12. Preskorn SH, Silkey B, Shah R, et al. Complexity of medication use in the Veterans Affairs Healthcare System: Part I: Outpatient use in relation to age and number of prescribers. J Psychiatr Pract 2005;11:5-15.
13. Silkey B, Preskorn SH, Golbeck A, et al. Complexity of medication use in the Veterans Affairs Healthcare System: Part II. Antidepressant use among younger and older outpatients. J Psychiatr Pract 2005;11:16-26.
14. Hanlon JT, Fillenbaum GG, Schmader KE, et al. Inappropriate drug use among community-dwelling elderly. Pharmacotherapy 2000;20:575-82.
15. Schmader K, Hanlon JT, Weinberger M, et al. Appropriateness of medication prescribing in ambulatory elderly patients. J Am Geriatr Soc 1994;42:1241-7.
16. Muijen M, Silverstone T. A comparative hospital survey of psychotropic drug prescribing. Br J Psychiatry 1987;150:501-4.
17. Willcox SM, Himmelstein DU, Woolhandler S. Inappropriate drug prescribing for the community-dwelling elderly. JAMA 1994;272:292-6.
18. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61:9-15.
19. Preskorn SH. A message from Titanic. Journal of Practical Psychiatry and Behavioral Health 1998;4:236-42.
20. Preskorn SH. Do you believe in magic? Journal of Practical Psychiatry and Behavioral Health 1997;3:99-103.
21. Preskorn SH. Polypharmacy in a patient with refractory major depression: Part I: The case. J Psychiatr Pract 2002;8:370-6.
22. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part II). J Psychiatr Pract 2003;9:228-36.
23. Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part I). J Psychiatr Pract 2003; 9:150-8.
24. Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions. J Psychiatr Pract 2003;9:376-83.
25. Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions (Part II). J Psychiatr Pract 2004;10:177-81.
26. Preskorn SH. The difference between the formal and the functional dose: The case of the patient on thioridazine and fluvoxamine. J Psychiatr Pract 2005;11:192-6.
27. Preskorn SH. Clinical application of the concept of relative potency: An example involving chlorpromazine and haloperidol. J Psychiatr Pract 2005;11:258-61.
28. Preskorn SH. I don't see 'em. Journal of Practical Psychiatry and Behavioral Health 1997;3:302-7.
29. Preskorn SH. Drug-drug interactions: Proof of relevance. J Psychiatr Pract 2005;11:116-22.
30. Preskorn SH, Baker B. Fatality associated with combined fluoxetine-amitriptyline therapy. JAMA 1997;277):682.
31. Ferslew KE, Hagardorn AN, Harlan GC, et al. A fatal drug interaction between clozapine and fluoxetine. J Forensic Sci 1998;48:383-6.
32. Preskorn SH. Fatal drug-drug interactions as a differential consideration in apparent suicides. J Psychiatr Pract 2002;8:233-8.
33. Spigset O, Hedenmalm K, Dahl ML, et al. Seizures and myoclonus associated with antidepressant treatment: Assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors. Acta Psychiatr Scand 1997;96:379-84.
34. Ahmed I, Dagincourt PG, Miller LG, et al. Possible interaction between fluoxetine and pimozide causing sinus bradycardia. Can J Psychiatry 1993;38:62-3.
35. Azaz-Livshits TL, Danenberg HD. Tachycardia, orthostatic hypotension and profound weakness due to concomitant use of fluoxetine and nifedipine. Pharmacopsychiatry 1997;30:274-5.
36. Beasley-CM J, Masica DN, Heiligenstein JH, et al. Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: Fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol 1993;13:312-20.
37. Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry 2003;18:264-5.
38. Reeves RR, Mack JE, Beddingfield JJ. Neurotoxic syndrome associated with risperidone and fluvoxamine. Ann Pharmacother 2002;36:440-3.
39. Stanford BJ, Stanford SC. Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine? J Psychopharmacol 1999;13:313-7.
40. Robinson RF, Nahata MC, Olshefski RS. Syncope associated with concurrent amitriptyline and fluconazole therapy. Ann Pharmacother 2000;34:1406-9.
41. Moskowitz H, Burns M. The effects on performance of two antidepressants, alone and in combination with diazepam. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12:783-92.
42. Spina E, Avenoso A, Scordo MG, et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction. J Clin Psychopharmacol 2002;22:419-23.
43. Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Saf 1991;6:460-2.
44. de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005;66:15-27.
45. Ludgate J, Keating J, O'Dwyer R, et al. An improvement in cognitive function following polypharmacy reduction in a group of epileptic patients. Acta Neurol Scand 1985;71:448-52.
46. Malek-Ahmadi P, Allen SA. Paroxetine-molindone interaction. J Clin Psychiatry 1995;56:82-3.
47. Johne A, Schmider J, Brockmoller J, et al. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol 2002;22:46-54.
48. Bertschy G, Baumann PA, Eap CB, et al. Probable metabolic interaction between methadone and fluvoxamine in addict patients. Ther Drug Monit 1994;16:42-5.
49. Preskorn SH, Silkey B. Multiple medications, multiple considerations. J Psychiatr Pract 2001;7:48-52.